New KEYTRUDA ® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology

Dateline City: KENILWORTH, N.J. Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral PresentationsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Dec. 3-6.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #MRK $MRK Keytruda MDS Merck pembrolizamab Source Type: news